The phase II TBCRC 048 trial (NCT03344965) assessed olaparib response in metastatic breast cancer patients with germline mutations of non-BRCA1/2 HR-related genes (cohort 1) and somatic mutations of BRCA1/2 or other HR-related genes (cohort 2). The gene discussed is BRCA1; the disease is breast carcinoma.